A Look At Jazz Pharmaceuticals (JAZZ) Valuation After Ziihera Priority Review Milestone

Jazz Pharmaceuticals (JAZZ) is back in focus after US regulators accepted a priority review of its supplemental biologics application for Ziihera in HER2-positive advanced gastroesophageal cancers, supported by pivotal Phase 3 HERIZON-GEA-01 data.

See our latest analysis for Jazz Pharmaceuticals.

Alongside the FDA priority review and a busy oncology conference schedule, Jazz Pharmaceuticals’ 1 month share price return of 7.68% and 90 day share price return of 23.24% feed into a 1 year total shareholder return of 68.86%, which may indicate building momentum rather than a short term spike.

If you are looking beyond a single oncology name, this could be a good moment to widen your search with the 33 healthcare AI stocks

With Jazz shares up 68.86% over 1 year and trading below the average analyst price target, the key question is whether Ziihera and the broader oncology pipeline still leave room for upside or if the market is already pricing in future growth.

Most Popular Narrative: 10.1% Undervalued

With Jazz Pharmaceuticals last closing at $202.72 against a narrative fair value of $225.53, the current setup centers on whether earnings and margins can catch up with that gap.

The expected approval and launches of multiple therapies (dordaviprone for H3 K27M mut diffuse glioma and Zepzelca in first line maintenance for small cell lung cancer) are set to drive new revenue streams and capitalize on unmet needs in rare cancers, supporting topline growth and improved earnings consistency. Ongoing investments in R&D, commercialization infrastructure, and international launches (such as rolling out Ziihera in BTC across Europe) are lowering barriers to entry in new geographies as healthcare access expands, positioning Jazz for steady long term market share and revenue growth.

Read the complete narrative.

Curious what sits behind that fair value uplift? The most followed narrative leans heavily on a profit swing, disciplined revenue build and a future earnings multiple that undercuts many large pharma names. Want to see which assumptions really do the heavy lifting in that story? Read on to test whether those building blocks line up with your own expectations.

Result: Fair Value of $225.53 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, this story can shift quickly if Oxybate competition bites harder than expected or if key oncology launches and trial timelines slip.

Find out about the key risks to this Jazz Pharmaceuticals narrative.

Next Steps

The narrative so far leans optimistic, but the real question is how you weigh the trade off between concern and opportunity. Take a moment to review both sides of the story with the 3 key rewards and 2 important warning signs

Looking for more investment ideas?

If Jazz has your attention, do not stop here. Broaden your watchlist now with other opportunities that match clear fundamentals and your own risk comfort.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com